CytomX Therapeutics Return on Tangible Equity 2014-2022 | CTMX
Current and historical return on tangible equity values for CytomX Therapeutics (CTMX) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
| CytomX Therapeutics Return On Tangible Equity Historical Data |
| Date |
TTM Net Income |
Tangible Equity |
Return on Tangible Equity |
| 2022-12-31 |
$-0.10B |
$-0.09B |
-761.54% |
| 2022-09-30 |
$-0.13B |
$0.03B |
-373.91% |
| 2022-06-30 |
$-0.13B |
$0.05B |
-233.48% |
| 2022-03-31 |
$-0.12B |
$0.07B |
-163.70% |
| 2021-12-31 |
$-0.12B |
$-0.00B |
-121.78% |
| 2021-09-30 |
$-0.07B |
$0.11B |
-67.75% |
| 2021-06-30 |
$-0.07B |
$0.13B |
-70.84% |
| 2021-03-31 |
$-0.06B |
$0.14B |
-84.07% |
| 2020-12-31 |
$-0.03B |
$0.05B |
-62.10% |
| 2020-09-30 |
$-0.05B |
$0.05B |
-98.18% |
| 2020-06-30 |
$-0.06B |
$0.06B |
-99.21% |
| 2020-03-31 |
$-0.08B |
$0.07B |
-102.70% |
| 2019-12-31 |
$-0.10B |
$0.05B |
-117.24% |
| 2019-09-30 |
$-0.10B |
$0.08B |
-92.74% |
| 2019-06-30 |
$-0.10B |
$0.10B |
-78.09% |
| 2019-03-31 |
$-0.08B |
$0.12B |
-74.21% |
| 2018-12-31 |
$-0.08B |
$0.13B |
-89.97% |
| 2018-09-30 |
$-0.05B |
$0.16B |
-64.94% |
| 2018-06-30 |
$-0.04B |
$0.04B |
-75.51% |
| 2018-03-31 |
$-0.05B |
$0.05B |
-94.69% |
| 2017-12-31 |
$-0.04B |
$0.07B |
-72.73% |
| 2017-09-30 |
$-0.06B |
$0.04B |
-95.00% |
| 2017-06-30 |
$-0.06B |
$0.05B |
-87.32% |
| 2017-03-31 |
$-0.05B |
$0.07B |
-61.45% |
| 2016-12-31 |
$-0.06B |
$0.08B |
-63.61% |
| 2016-09-30 |
$-0.06B |
$0.09B |
-54.55% |
| 2016-06-30 |
$-0.06B |
$0.10B |
-59.84% |
| 2016-03-31 |
$-0.05B |
$0.11B |
-72.08% |
| 2015-12-31 |
$-0.04B |
$0.12B |
-99.42% |
| 2015-06-30 |
$-0.02B |
|
inf% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.118B |
$0.053B |
|
CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered in South San Francisco, California.
|
